A recent Cochrane review suggests that the use of an antimicrobial dressing instead of a non-antimicrobial dressing may increase the number of diabetic foot ulcers (DFUs) healed over a medium-term follow-up period. 7 Several dressing types are available to treat DFUs, and silver dressings are being used increasingly as adjunctive, antimicrobial therapy to antibiotics in wounds that are clinically infected or at risk of infection. 8 Ionic silver is an antiseptic that kills bacteria by several mechanisms and appears to be incorporated into the bacterial cell wall and bacterial DNA, thereby blocking vital metabolic processes and cell proliferation. 9, 10 On the other hand, the silver ions promote a faster wound contraction due to accelerated proliferation and differentiation of fibroblasts into myofibroblasts. 11 Some systematic reviews and meta-analyses have found that silver dressings significantly reduce odor, improve painrelated symptoms, decrease wound exudate, and have a prolonged dressing wear time compared with alternative wound treatments in nonhealing and infected chronic wounds. 12, 13 Despite the fact that silver dressings are increasingly used nowadays in patients with DFUs, there is limited clinical evidence to support our daily clinical practice. Jude et al 14 reported the first prospective randomized controlled study undertaken of a silver-containing dressing in DFUs. This study showed the first significant clinical effects of a primary wound dressing containing silver on DFU healing, specifically in ulcer depth reduction and in infected ulcers requiring antibiotic treatment. In a randomized controlled trial, Gottrup et al suggested that collagen/ oxidized regenerated cellulose/silver treatment normalizes the wound microenvironment and protects against infection, resulting in improved wound healing. 15 Lázaro-Martínez et al found that the use of a silver alginate dressing promotes healing on DFU with local infection, reducing the inflammatory clinical signs significantly over a period of 3 weeks. 16 However, although the clinical effects of the silver dressing in the treatment of the DFU is widely accepted, there are no studies so far that evaluate the effect of the antimicrobial dressing on the bacterial burden control and its influence in the clinical evolution of the wounds. The aim of the present study was to evaluate the clinical and microbiological efficacy of a silver foam dressing with silicone adhesive in the management of DFU with mild infection. In the case that the patients were taking antibiotics previously at inclusion to the study, antibiotics were stopped for at least 48 hours before. Previous antimicrobial dressings were removed before including to the study for at least 7 days.
Patients and Methods

Patients
DFU Assessment
Sensorimotor neuropathy of DFU was diagnosed using a Semmes-Weinstein 5.07/10g monofilament and a biothesiometer (both from Novalab Iberica, Spain). Patients who failed to feel 1 of the 2 tests were diagnosed with neuropathy.
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The Ankle-Brachial Index and Toe-Brachial Index were assessed using a manual 8 MHz Doppler (Doppler II, Huntleigh Healthcare Ltd, UK), and the toe systolic pressure was taken with a digital plethysmography (Systoe, Atys Medical, Madrid).
Wound Management
All patients received standard of care for their wounds consisting of debridement and proper off-loading (nonremovable walker cast or postsurgical shoes depending of the location of DFUs) as per the International Working Group of the Diabetic Foot guidelines. 21 All wounds were cleansed with sterile saline prior to assessment and dressing application. A silver foam dressing with silicone adhesive (Biatain Silicone Ag, Coloplast, Humlebaek, Denmark) was applied twice per week for wound management during a 6-week treatment period. After the study period, patients were treated with moist wound dressings without silver twice per week and were followed until ulcers healed, with healing defined as complete epithelialization without any drainage sustained or up to a maximum of 18 weeks after the end of the study period.
Outcomes
The main outcome of our study was to evaluate the efficacy of the use of an antimicrobial silver dressing in the reduction of the bacteria burden and the clinical evolution of the DFU after 6 weeks of treatment.
Methods for Taking of Tissue Samples and Microbiological Analysis
Soft tissue punch biopsies (2 mm) were taken from the wound bed, at the central base (deep part of the wound). Samples were obtained every second week (weeks: 0, 3, and 6) during a 6-week treatment period. Following tissue collection, samples were immediately transported to the microbiological laboratory for qualitative and quantitative microbiological analysis.
Tissue samples were weighed and mechanically homogenized in 0.5 mL sterile phosphate-buffered saline (Sigma Aldrich, St Louis, MO). Homogenates were serially diluted in phosphate-buffered saline (1:10-1:100), and diluted and undiluted samples were plated onto Columbia agar (BD, Sparks, MD), Columbia agar supplemented with colistin and nalidixic acid (BD) and MacConkey agar (MCK, BD), using a spiral plater workstation (Don Whitley Scientific, Shipley, UK). Plates were incubated for 24 hours at 37°C prior to species-specific colony counting. Grown colonies with different morphology on agar plates with selective media for gram-positive (colistin and nalidixic acid) and gram-negative organisms (MCK) were subcultured on Columbia agar plates for an additional 24 hours. Pure microorganisms were identified by standard microbiological procedures and/or by using the BBL Crystal identification system (BD). The specific enumeration of organisms was directly performed on the Columbia agar plates using a stereomicroscope (SteREO Discovery V.8, Carl Zeiss Microimaging, Germany), after comparing the morphology of grown colonies with those observed in the pure cultures from qualitative analysis. The limit of detection was 10 colony-forming units (CFU) per tissue sample. Susceptibility testing of Staphylococcus aureus isolates for oxacillin was performed according to the Clinical and Laboratory Standards Institute guidelines, using a 30 g cefoxitin disc and Mueller-Hinton agar. 22 Results were expressed as logarithms CFU per gram of tissue (Log 10 CFU/g).
Evaluation of Wound Conditions
Wounds were assessed at patient admission, and wound bed tissue was evaluated for presence, quality, and consistency of granulation tissue, using a validated wound scoring system (Table 1) , with scores between a minimum of 0 points and a maximum of 7 points. 23 In addition, wounds were assessed for the amount of wound exudate, and for periwound skin conditions (perilesional skin maceration). Wet bandages and saturated dressings were registered. Wound healing was monitored weekly during the 6-week treatment period, and planimetric measurements of wound size were conducted using Visitrak (Smith & Nephew, Hull, UK), with the area of the lesion determined with an approximation of ±5 mm 2 .
Ethical Considerations
This study was conducted in accordance with the Declaration of Helsinki (2013 revision) and followed all local laws and regulations in clinical research investigations in patients. 24 The study protocol received full approval from the Ethics Committee of the Hospital Clínico San Carlos (16/532-P).
Statistical Analysis
Statistical analysis was performed using SPSS for IOs, version 21.0 (SPSS, Inc, Chicago, IL). Qualitative variables were described using frequency distributions and percentages, and quantitative variables were described by their mean, standard deviation, first quartile, and third quartile. A Student's matched pairs test was performed for samples to compare the averages of the quantitative variables with normal distribution and a Wilcoxon's test was performed for samples to compare averages of quantitative variables with 
Results
Patient Population
A total of 21 participants were included in this study. The mean age of participants was 63 ± 7.6 years, 17 (80.9%) of 21 were men, and 20 (95.2%) had type 2 diabetes. The mean duration of diabetes was 13.9 ± 10.4 years, the mean HbA1c was 61 ± 4 mmol/mol (7.7 ± 1.8%), and the mean glucose level was 8.4 ± 3.6 mmol/L. Seventeen patients (80.9%) had neuropathy, 18 patients had hypertension (85.7%), 5 patients had retinopathy (23.8%), and 13 patients had dyslipidemia (61.9%).
Of the 21 participants included in the study, 19 completed the 6-week treatment period and 2 patients were excluded of the study due to the presence of cellulitis during the treatment period.
Wound Condition and Wound Size
According to Texas Classification 13 ulcers (61.9%) were type IIB and 8 ulcers (38.1%) were IID with a mean wound duration of 22.4 weeks (range 4-36 weeks). In our study population, 7 (33.3%) DFUs were located in the rear foot, 1 (4.8%) in the mid foot, 8 (38.1%) in the metatarsal area, and 5 (23.8%) in the hallux. Table 2 illustrates the characteristics of the ulcers at patient inclusion (week 0) and at the end of the study (week 6). Clinical evaluation revealed improvements in wound conditions as a result of treatment with the silver dressing. During the treatment period, Wollina wound scores improved significantly, from a mean score of 3.9 ± 1.6 points at inclusion to 6.1 ± 1.3 points at the end of the study (n = 19, P < .001). In 2 patients, the Wollina score did not improve during the treatment period, in one of them the Wollina score was 4 at week 0 and 4 at week 6, and in the other one the Wollina score was 5 at week 0 and 3 at week 6. Mean wound sizes were 2.7 cm 2 (1.1; 3.5) at week 0, and 0.98 cm 2 (0.3; 1.2) at week 6, with significant wound surface area reduction during the treatment period (P = .001). Figure 1 shows the percentage of patients who achieved at least 50% reduction in wound area from baseline throughout the treatment period, and Figure 2 depicts the mean percentage decrease in wound area from baseline per week in our study population. Seventeen patients (89.5%) progressed well according to Wollina Score and 7 of those patients healed during the 6-week study period (Figure 3) . The mean time to healing in our study population was 10.1 (5.25, 16) weeks, and when we stratified among patients with yes or no ≥50% reduction in wound area by week 4, the mean time to healing was 7.6 (4.2, 10.7) weeks and 17.5 (13, 22.5) weeks, respectively, with significant difference in time to healing (P = .019). Nonclosure was observed in 3 patients during the posttreatment follow-up (1 patient developed critical limb ischemia and required a revascularization treatment, 1 patient suffered a heart attack and we lost the follow-up, and 1 patient required surgical treatment due to diabetic foot osteomyelitis).
Microbiological Analysis of Tissue Samples
Clinical improvements of DFUs treated with silver dressing were accompanied by changes in the number of species recovered and in the bacterial load of infected wounds (Figures 4 and 5) . At week 0, 84.2% DFU specimens were polymicrobial yielding 2 to 4 organisms. The predominant gram-positive organisms were Corynebacterium sp (47.4%), S aureus (42.1%), including a methicillin-resistant S aureus (MRSA) isolated in 1 patient, and, less frequently coagulase-negative staphylococci (CoNS, 21.0%). Among gram-negative rods (36.8% of the total organisms), members of the family of Enterobacteriaceae were the predominant group (21.0%) followed by nonfermenting gram-negative bacilli (NFGNB) group (15.8%), including the isolation of Pseudomonas aeruginosa (5.3% of total organisms). At week 6, S aureus (26.3%), members of Enterobacteriaceae group (5.3%), and NFGNB other than P aeruginosa (5.3%) were recovered less frequently, while the frequency of isolation of CoNS (47.4%), Streptococcus sp (10.53%), Corynebacterium sp (47.4%), MRSA (5.3%), and P aeruginosa (5.3%) increased or remained unchanged.
As seen in the upper portion of the Figure 5 , the treatment with silver dressing contained the basal bioburden of DFUs in all patients who completed the study period (0.1 Log 10 CFU/g reduction at week 6 vs baseline) and irrespective of the clinical evolution of our study population in the follow-up (0.0 and 0.5 Log 10 CFU/g reduction for patients with favorable and unfavorable clinical outcome, Figure 5 , middle plots).
Moreover, silver dressing treatment resulted in speciesspecific bioburden changes in DFUs. As shown in Figure 4 , the bioburden of classically considered DFU pathogenic organisms was significantly reduced (P = .0148) at week 6; substantial decrease in the load of S aureus (1.1 ± 1.8 Log 
Discussion
This study has demonstrated that the use of a silver foam dressing with silicone adhesive has a clinical and microbiological efficacy in a case series of patients with DFUs. The main arguments against using topical antiseptics are the lack of adequate proof of efficacy and residual concerns about their potential toxicity to healing wounds. 6 Regarding the clinical effectiveness, in our study population wound scores improved significantly, from a mean score of 3.9 ± 1.6 points at inclusion to 6.1 ± 1.3 points at the end of the study (n = 19, P < .001). Furthermore, we observed a significant decrease in exudate levels (38.8% of patients with high exudate levels at inclusion vs 5.3% at the end of the study, P = .0031) and in the mean ulcer size (2.27 cm 2 at inclusion vs 0.99 cm 2 at the end of the study, P = .001). Snyder et al reported that 50% reduction in wound area from baseline to week 4 is a good prognostic indicator of wound healing. 25 In our study population, 63.2% (12/19) and 78.9% (15/19) of patients had at least 50% reduction in wound area at weeks 4 and 6, respectively (P = .010), and the mean wound reduction was 60.4% and 70.6% at weeks 4 and 6, respectively (P < .001). Wound area reduction was comparable to a previous noncomparative study in DFUs with a similar nonadhesive silver foam dressing, where a 56% reduction in 4 weeks was observed. 26 Gottrup et al 15 found similar results in terms of 50% reduction in wound by week 4 (79%, n = 19/24) when compared with control group (43%, n = 6/14) in a randomized controlled trial using a collagen/oxidized regenerated cellulose/silver treatment in patients with DFUs. Based on our results, we consider, like Snyder et al, 25 that 50% reduction in wound area by week 4 is a good prognostic indicator of wound healing. We found significant difference in time to healing among patients with a target reduction in wound area by week 4 of ≥50%, 7.6 (4.2, 10.7) weeks versus 17.5 (13, 22.5) weeks, respectively (P = .019). In our study population, 17 patients (89.5%) showed good wound progress, and 7 (36.8%) of these healed during the 6-week treatment period. In 2 patients, the Wollina score did not improve during the treatment period, one patient developed critical limb ischemia and required a revascularization treatment and the other patient required surgical treatment due to diabetic foot osteomyelitis during the follow-up period. The mean time to healing in our study population was 10.1 (5.25, 16) weeks. Jude et al 14 reported shorter time to healing (53 days) in patients with DFUs using a silver dressing in a prospective randomized controlled study. The main difference from our study is that patients in their study received systemic antibiotics and our patients did not receive systemic antibiotic treatment during the study. We consider, like Jude et al, that the more positive effects of a silver dressing on overall wound condition for the patients initially prescribed antibiotics might be expected from use of a dressing, which absorbs and holds wound exudate. In this regard, the capacity to absorb, retain, and kill bacteria in infected wound fluid in the silver dressing may work in synergy with systemic antibiotics, which may not always reach microorganisms on the wound surface. 14, 27 In our study, patients did not receive systemic antibiotic treatment because we also analyzed the microbiological effects of the silver dressing, and the systemic antibiotic treatment could have altered the microbiological results.
We observed that use of the silver dressing resulted in significant decreases at week 6 (P = .0148) in the bioburden of classically considered DFU pathogenic organisms such as S aureus (1.1 ± 1.8 Log Based on these results, we have demonstrated efficacy of the silver dressing against several common wound pathogens in DFUs, and in this sense, this dressing may also prove helpful with the increasing problem of multidrug-resistant microorganisms that are untreatable with most systemic agents. To our knowledge, this is the first study that has evaluated the microbiological effects of silver dressing in patients with DFU. Some in vitro tests of iodides, silver, and hydrogen peroxide have demonstrated a potent antibacterial activity. 6 Ziegler et al 28 reported effectiveness of a silvercontaining polyamide dressing against MRSA as well as numerous other gram-positive and gram-negative bacteria in vitro test. A recent study on preclinical evaluation of silver dressing in porcine model showed that a new gelling fiber dressing with silver was effective in reducing biofilmassociated P aeruginosa. 29 It has been reported that biofilm formation occurs in 60% of chronic wounds and 77% of DFUs. 30 Although mechanical debridement before sampling should reduce, if not eliminate, the biofilm formed, 31 we assumed that, under the assumption that most of DFUs presented in our study exhibited biofilms, the dressing was also active against bacteria embedded in biofilms. However, this should be specifically assessed in a future study since we did not perform a direct measure of biofilm occurrence.
We found that the changes in pathogenic bioburden was accompanied by slight reductions in the load of Corynebacterium sp in wounds and by strong increases in CoNS bioburden. Unlike topical antibiotics, a recent experimental model demonstrated that antiseptics, despite their indiscriminate mechanisms of action and broad antimicrobial spectrum, elicit only modest changes to skin bacterial community structure and, moreover, a slower and less aggressive decolonization of Staphylococcus spp, which are the dominant aerobic members of indigenous skin flora. 32 As in our patients, this effect could be the result of rapid repopulation of the treated area from surrounding tissues, which is likely to occur when available antiseptic concentrations allow that the bacterial multiplication rate to exceed the kill rate of resident organisms. Rather than being problematic, ulcer repopulation with skin resident microorganisms is clinically beneficial because it provides greater resistance to subsequent colonization by pathogenic organisms. 32 On the other hand, the treatment with silver dressing contained the basal bioburden of DFUs in all patients who completed the study period irrespective of the clinical evolution during the follow-up (0.0 and 0.5 Log 10 drop for patients with favorable and unfavorable clinical outcome, respectively). We know that the healing in DFUs will occur due to 3 conditions: adequate arterial inflow, appropriate control of infection, and off-loading of the site of wound and immediate surrounding area is satisfied. 33 In this regard, one of the patients with unfavorable clinical evolution developed critical limb ischemia and required a revascularization treatment and another patient required surgical treatment due to diabetic foot osteomyelitis.
In our study population, 2 patients were excluded due to the presence of cellulitis during the treatment period because they requested systemic antibiotic treatment. Actually it is uncertain whether use of an antimicrobial dressing affects the risk of adverse events compared with use of a non-antimicrobial dressing over a medium-term observation period in patients with DFU. 7 Regarding the potential toxicity of silver dressing to healing wounds, we know that the amount of silver release can be controlled by various means, most notably by increasing the surface of the incorporated silver preparation. 28 Nanocrystalline silver dressings have been shown to release high amounts of silver ions over a short period of time and this could be associated with significant cytotoxicity. 28, 34 On the other hand, Ziegler et al 28 and Dong et al 35 have reported that low-silver-releasing ointment dressing has less toxicity than other dressings surrounding wound tissues. The silver dressing used in our study has a sustained silver release profile up to 7 days in the presence of exudate. A similar sustained silver-release dressing has shown positive clinical results in nonhealing wounds with signs of infection in several comparative clinical studies. 36, 37 Currently, the balance between antimicrobial activity and cellular toxicity remains a challenge for developing new products, which may interfere less with normal wound healing processes. In this sense, given that unlike antimicrobials the resistance to antiseptics containing silver is rare and sporadic, 38 we think that the balance between the benefit, that is, reduction of pathogenic bacterial load and prevention of the emergence of resistant organisms, and the risk for adverse effects or toxicity on the patient, is favorable to the use of this silver dressing.
The main limitation of this study is that it did not involve a control group that received local treatment with dressings without silver. We have included sharp debridement as a fundamental part of our standard DFU management, and for this reason, we think that the role of anaerobic bacteria in the wound healing could be lower than aerobic bacteria in our study population. Kalan et al observed that sharp debridement therapy depleted anaerobic bacteria in wounds with favorable outcomes, suggesting that successful debridement may disrupt anaerobic networks. 39 Conversely, the main strength is that this is the first study that has evaluated the microbiological effects of a silver dressing in a case series of patients with DFUs. The authors consider that properly designed randomized controlled trials are necessary to evaluate the clinical and microbiological effects of silver dressings in the treatment of patients with diabetic foot infection.
We conclude that the use of a silver foam dressing with silicone adhesive significantly reduced the pathogenic bacterial load and markedly improved the clinical outcome in patients with diabetic foot ulcer with mild infection over a 6-week treatment period.
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